Page 390 of 439: studies 3,891 to 3,900 of 4,389, newest first. Back to the psilocybin overview
Royal Society of Chemistry eBooks July 22, 2022
Tryptamine (2-(1H-indol-3-yl)ethan-1-amine) is a naturally-occurring metabolite of the amino acid tryptophan, which, in turn, is a constituent of many proteins. Although tryptamine has few significant pharmacological properties, it forms the parent nucleus of a number of hallucinogenic drugs. Some of these tryptamines are derived from plant material or animals and have been used in certain...
July 22, 2022
The word ‘misuse’ as used in many Anglophone countries signifies the non-authorised use of medicines that can, in appropriate circumstances, be legally used. By contrast, The World Health Organization prefers the term ‘abuse’. Depending on the jurisdiction, the substances in question are referred to as either scheduled or controlled drugs. Overall drug use by adults in England and Wales has...
July 22, 2022
Concurrent with the Misuse of Drugs Act 1971 (MDAct), several further pieces of legislation were introduced, principally the Drugs Act 2005, Temporary Class Drug Orders 2011 (TCDOs) and the Psychoactive Substances Act 2016 (PSA). Before 2005, the cultivation of ‘magic mushrooms’ was not an offence. Whether a person was in possession of such mushrooms depended on whether they were in possession...
bioRxiv (Cold Spring Harbor Laboratory) July 13, 2022 Andrea I. Luppi, Justine Y. Hansen, Ram Adapa et al. 5 citations preprint
Abstract To understand how pharmacological interventions can exert their powerful effects on brain function, we need to understand how they engage the brain’s rich neurotransmitter landscape. Here, we bridge microscale molecular chemoarchitecture and pharmacologically-induced macroscale functional reorganisation, by relating the regional distribution of 19 neurotransmitter receptors and...
Insight the psychological dimensions of society July 12, 2022 Олег Вікторович Орлов 1 citation
Метою дослідження є характеристика методу РАТ (Psychedeilc Assisted Therapy) та окреслення перспектив його впровадження в Україні. Методологія та методи. Використано методи теоретичного аналізування наукової літератури. Результати. З’ясовано, що за попередніми оцінками, щонайменше 23.5 млн. українських громадян ризикують зустрітися з погіршенням психічного здоров’я: до 20.0% з них – середнього...
Frontiers in Psychiatry July 12, 2022 Kwonmok Ko, Gemma Knight, James Rucker et al. 296 citations
The mystical experience is a potential psychological mechanism to influence outcome in psychedelic therapy. It includes features such as oceanic boundlessness, ego dissolution, and universal interconnectedness, which have been closely linked to both symptom reduction and improved quality of life. In this review, 12 studies of psychedelic therapy utilizing psilocybin, ayahuasca, or ketamine were...
Preprints.org July 5, 2022 Ravi Philip Rajkumar 1 citation preprint
Suicidal behaviour is a public health problem whose magnitude is both substantial and increasing. Since many individuals seek medical treatment following a suicide attempt, strategies aimed at reducing further attempts in this population are a valid and feasible secondary prevention approach. An evaluation of the available evidence suggests that existing treatment approaches have limited...
ACS Omega July 5, 2022 Grant C. Glatfelter, Duyen N. K. Pham, Donna Walther et al. 14 citations
Aeruginascin (4-phosphoryloxy-N,N,N-trimethyltryptammonium) is an analogue of psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) that has been identified in several species of psilocybin-containing mushrooms. Our team previously reported the synthesis, structural characterization, and biological activity of the putative metabolite of aeruginascin (4-hydroxy-N,N,N-trimethyltryptammonium;...
Indian Journal of Psychiatry July 1, 2022 Gokul Raj 3 citations
Sir, Psychedelic studies have reported positive results for depression and anxiety related to cancer and other life-threatening illnesses, treatment-resistant depression, and tobacco and alcohol dependence.[1] Although there are no active psychedelic research studies going on in India, there is growing interest about these substances as evident by numerous social media groups and pages with a...
Journal of Substance Abuse Treatment July 1, 2022 Patrick Köck, Katharina Froelich, Marc Walter et al. 68 citations
Iboga and its primary alkaloids, ibogaine and noribogaine, have been of interest to researchers and practitioners, mainly due to their putative efficacy in treating substance use disorders (SUDs). For many SUDs, still no effective pharmacotherapies exist. Distinct psychoactive and somatic effects of the iboga alkaloids set them apart from classic hallucinogens like LSD, mescaline, and...